ECSP024384A - INHIBIDORES DE HMG - CoA REDUCTASA Y METODO - Google Patents

INHIBIDORES DE HMG - CoA REDUCTASA Y METODO

Info

Publication number
ECSP024384A
ECSP024384A EC2002004384A ECSP024384A ECSP024384A EC SP024384 A ECSP024384 A EC SP024384A EC 2002004384 A EC2002004384 A EC 2002004384A EC SP024384 A ECSP024384 A EC SP024384A EC SP024384 A ECSP024384 A EC SP024384A
Authority
EC
Ecuador
Prior art keywords
inhibitors
cholesterol
reductasa
coa reductasa
hmg
Prior art date
Application number
EC2002004384A
Other languages
English (en)
Inventor
Jeffrey A Robl
Bang-Chi Chen
Chong-Qing Sun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP024384A publication Critical patent/ECSP024384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Los compuestos de la siguiente estructura son inhibidores de la HMG CoA REDUCTASA, LOS CUALES DON ACTIVOS EN LA INHIBICIÓN DE LA BIOSÍNTESIS DEL COLESTEROL, regulando los lípidos del suero sanguíneo, como disminuyendo el colesterol LDL y /o aumentando el colesterol HDL y tratando la hiperlipidemia, hipercolesterolemia, hipertrigliceridemia y aterosclerosis y sales aceptables farmacéuticamente parecidas, en las cuales X es O o Z es n es 0 o 1; R1 y R2 son los mismos o diferentes y son independientes seleccionados de alquil, arilalquil, cicloalquil, alquenil, cicloalquenil, aril, heteroaril o cicloheteroalquil; y R3 R9 como se definen aqui.
EC2002004384A 2000-06-15 2002-12-13 INHIBIDORES DE HMG - CoA REDUCTASA Y METODO ECSP024384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21159500P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
ECSP024384A true ECSP024384A (es) 2003-03-31

Family

ID=22787569

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004384A ECSP024384A (es) 2000-06-15 2002-12-13 INHIBIDORES DE HMG - CoA REDUCTASA Y METODO

Country Status (22)

Country Link
US (1) US20020013334A1 (es)
EP (1) EP1294728A1 (es)
JP (1) JP2004503557A (es)
KR (1) KR20030036225A (es)
CN (1) CN1436192A (es)
AR (1) AR030700A1 (es)
AU (1) AU2001266858A1 (es)
BR (1) BR0111599A (es)
CA (1) CA2412632A1 (es)
CZ (1) CZ20023930A3 (es)
EC (1) ECSP024384A (es)
HU (1) HUP0302937A2 (es)
IL (1) IL152490A0 (es)
MX (1) MXPA02012252A (es)
NO (1) NO20026012L (es)
NZ (1) NZ523627A (es)
PE (1) PE20020254A1 (es)
PL (1) PL359820A1 (es)
RU (1) RU2003101064A (es)
UY (1) UY26777A1 (es)
WO (1) WO2001096347A1 (es)
ZA (1) ZA200210103B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677298B2 (en) * 2000-07-20 2004-01-13 Bristol-Myers Squibb Company Regulators of PPARδ (β) and their use in the treatment of obesity and insulin resistance
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
MXPA03006727A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
PT1353694E (pt) * 2001-01-26 2008-03-12 Schering Corp Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares
ES2286233T3 (es) * 2001-01-26 2007-12-01 Schering Corporation Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares.
EP1864680A3 (en) * 2001-01-26 2012-03-28 Schering Corporation Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
IL158525A0 (en) * 2001-06-06 2004-05-12 Bristol Myers Squibb Co A process for preparing chiral diol sulfone derivatives
GB0119460D0 (en) 2001-08-09 2001-10-03 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
BR0215258A (pt) 2001-12-21 2004-12-07 Pharmacia Corp Moduladores de receptor x de fìgado de tioéter aromático
US20060058369A1 (en) * 2002-02-19 2006-03-16 Vanderbilt University Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors
JP5113979B2 (ja) 2002-02-28 2013-01-09 ユニバーシティ オブ テネシー リサーチ ファウンデーション 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
EP1487407A4 (en) * 2002-03-12 2010-08-25 Microdose Therapeutx Inc SITE SPECIFICITY ADMINISTRATION OF MEDICAMENTS SIMULTANEOUSLY TAKEN BY INHALATION
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
CA2486651A1 (en) * 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
MXPA04011691A (es) * 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US6933292B2 (en) * 2002-07-30 2005-08-23 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
DE60313339T2 (de) * 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20040110947A1 (en) * 2002-09-17 2004-06-10 Pharmacia Corporation Aromatic liver X-receptor modulators
AU2003273675A1 (en) * 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
GB0228894D0 (en) * 2002-12-11 2003-01-15 Avecia Ltd Process
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
PT1587584E (pt) * 2003-01-16 2007-06-11 Boehringer Ingelheim Int Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
RU2006105646A (ru) * 2003-07-23 2007-09-10 Экселиксис, Инк. (Us) Производные азепина в качестве фармацевтических агентов
US20080058292A1 (en) * 2003-10-29 2008-03-06 Raif Tawakol Method for increasing HDL and HDL-2b levels
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20060058283A1 (en) * 2004-09-15 2006-03-16 Zymes, Inc. Compositions comprising ubiquinones
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2008059519A2 (en) * 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
KR100900044B1 (ko) 2007-07-05 2009-06-01 한국식품연구원 3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
WO2009079765A1 (en) * 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CN102698276B (zh) * 2008-01-03 2014-12-10 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
US9551721B2 (en) * 2009-06-02 2017-01-24 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
EP3431128A1 (en) * 2010-01-05 2019-01-23 MicroDose Therapeutx, Inc. Inhalation device and method
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR101292238B1 (ko) * 2010-07-01 2013-07-31 주식회사유한양행 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 그의 중간체의 제조방법
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103360384A (zh) * 2013-07-30 2013-10-23 浙江京新药业股份有限公司 HMG-CoA还原酶抑制剂关键中间体的合成方法
CN106822903B (zh) * 2017-02-13 2019-07-23 牡丹江医学院 用于治疗心衰的药物组合物及其应用
CN107164544A (zh) * 2017-07-18 2017-09-15 孙葆青 通过高通量测序快速检测阿托伐他汀钙的敏感性的方法
CN112005029B (zh) 2018-04-27 2022-02-18 三之星机带株式会社 多楔带及其用途
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用
CN114213350B (zh) * 2021-12-29 2024-03-19 江苏福瑞康泰药业有限公司 一种他汀类药物中间体的制备方法
CN114437052B (zh) * 2021-12-31 2024-03-29 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种利用连续流微通道反应器合成他汀类药物中间体的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
ZA911046B (en) * 1990-02-26 1992-10-28 Squibb & Sons Inc Quinoline and pyridine anchors for hmg-coa reductase inhibitors
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine

Also Published As

Publication number Publication date
NZ523627A (en) 2004-10-29
AU2001266858A1 (en) 2001-12-24
MXPA02012252A (es) 2003-06-06
CN1436192A (zh) 2003-08-13
IL152490A0 (en) 2003-05-29
UY26777A1 (es) 2002-01-31
PL359820A1 (en) 2004-09-06
NO20026012D0 (no) 2002-12-13
NO20026012L (no) 2003-02-03
US20020013334A1 (en) 2002-01-31
KR20030036225A (ko) 2003-05-09
RU2003101064A (ru) 2004-08-10
PE20020254A1 (es) 2002-04-03
ZA200210103B (en) 2004-03-12
BR0111599A (pt) 2004-10-13
HUP0302937A2 (hu) 2003-12-29
EP1294728A1 (en) 2003-03-26
WO2001096347A1 (en) 2001-12-20
JP2004503557A (ja) 2004-02-05
AR030700A1 (es) 2003-09-03
CZ20023930A3 (cs) 2003-03-12
CA2412632A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
ECSP024384A (es) INHIBIDORES DE HMG - CoA REDUCTASA Y METODO
MXPA02012415A (es) Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y su uso como medicamentos para el tratamiento de enfermedades relacionadas con el colesterol.
DK0521471T3 (da) Pyrimidinderivater som HMG-CoA-reduktase-inhibitorer
DE602004018617D1 (de) Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
BR9909961A (pt) Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ATE177420T1 (de) Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase
EA200500178A1 (ru) Новые соединения, содержащие их фармацевтические композиции и способы их применеия
DE60131160D1 (de) Caspase-inhibitoren und ihre verwendungen
HK1085727A1 (en) Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
NO911121L (no) Nye squalensyntetaseinhibitorer
DK0842661T3 (da) Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning
BR9611790A (pt) Composto derivados de anilidas processo de preparação e utilização dos mesmos e composições farmacêuticas
ATE273281T1 (de) Heterozyklische cytotoxische wirkstoffe
DE69717101T2 (de) VERWENDUNG VON alpha-ALKYLGLUCOSIDEN UND DEREN ESTERN ALS ANTIMIKROBIELLE EMULGATOREN
DE69815509D1 (de) Heterozyklische verbindungen die als oxido-squalen-zyklase-inhibitoren anwendung finden
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
DE69824901D1 (de) Cholesterin Esterase Inhibitoren
PT1551850E (pt) 2 oxo-voruscharina e seus derivados
TH60766A (th) สารยับยั้ง HMG-CoA รีดักเทส และวิธีการยับยั้ง